243
Participants
Start Date
December 21, 2018
Primary Completion Date
November 29, 2024
Study Completion Date
February 26, 2027
Durvalumab
Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
Capivasertib
Capivasertib oral bid 4-week cycles; 3 weeks on (dosing on days 2,3,4 and 5) and 1 week off
Oleclumab
Oleclumab iv Every 2 weeks (q2w) for first 2 cycles (days 1 and 15 in cycles 1 and 2), then every 4 weeks (q4w) starting at cycle 3 day 1
Paclitaxel
Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off
Trastuzumab deruxtecan
Trastuzumab deruxtecan iv 3-week cycles (once weekly) q3w
Datopotamab deruxtecan
Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w
Research Site, Taipei
Research Site, Taoyuan District
Research Site, Taipei
Research Site, Columbia
Research Site, Williamsburg
Research Site, Taichung
Research Site, Grand Rapids
Research Site, St Louis
Research Site, Tainan City
Research Site, Dallas
Research Site, Kaohsiung City
Research Site, Tucson
Research Site, Boston
Research Site, Boston
Research Site, Kelowna
Research Site, London
Research Site, Greenfield Park
Research Site, Montreal
Research Site, Gdansk
Research Site, Krakow
Research Site, Lublin
Research Site, Opole
Research Site, Rzeszów
Research Site, Warsaw
Research Site, Warsaw
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Cambridge
Research Site, London
Research Site, Manchester
Research Site, Oxford
Lead Sponsor
AstraZeneca
INDUSTRY